Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$44.15
$44.17
$16.02
$45.23
$913.91M1.03704,539 shs1.24 million shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.43
-0.3%
$26.19
$23.14
$30.93
$3.64B0.461.46 million shs745,811 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$49.60
-1.2%
$48.04
$28.72
$58.38
$3.98B0.51861,615 shs1.15 million shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$36.01
+4.2%
$32.89
$16.01
$44.34
$3.81B0.96903,563 shs750,956 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00%0.00%0.00%0.00%0.00%
Perrigo Company plc stock logo
PRGO
Perrigo
-0.32%-1.04%-0.34%-3.01%+2.52%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-1.20%-4.38%+7.99%-11.85%+35.82%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
+4.23%-11.37%+14.97%+1.72%+93.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
4.632 of 5 stars
2.13.04.23.52.91.72.5
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
4.6297 of 5 stars
4.34.00.04.41.80.81.3
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.291 of 5 stars
3.41.00.00.03.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00
N/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0024.86% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.67
Moderate Buy$65.0031.05% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.75
Moderate Buy$47.3731.54% Upside

Current Analyst Ratings Breakdown

Latest ALBO, PTCT, ZLAB, and PRGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
5/27/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.00
5/9/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$55.00 ➝ $68.00
5/8/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$50.00 ➝ $40.00
4/22/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$65.00 ➝ $65.00
3/27/2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$40.58M22.52N/AN/A$9.11 per share4.85
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.83$5.03 per share5.25$31.66 per share0.83
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$806.78M4.87N/AN/A($14.24) per share-3.48
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$398.99M9.96N/AN/A$7.68 per share4.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$171.80M-$1.31N/A8.64N/A-4.16%8.93%3.87%8/1/2025 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$363.30M$6.517.62N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/5/2025 (Estimated)

Latest ALBO, PTCT, ZLAB, and PRGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
5/6/2025Q1 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.85$10.04+$9.19N/A$437.16 million$1.18 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.39%N/AN/A 23 Years
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A

Latest ALBO, PTCT, ZLAB, and PRGO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/A
6.32
6.23
Perrigo Company plc stock logo
PRGO
Perrigo
0.82
2.36
1.28
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.89
3.85
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
3.26
3.09

Institutional Ownership

CompanyInstitutional Ownership
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
94.25%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
6.90%
Perrigo Company plc stock logo
PRGO
Perrigo
0.40%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.50%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
4.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
13020.70 million19.27 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,379137.48 million136.93 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.26 million74.90 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,869110.33 million104.86 millionOptionable

Recent News About These Companies

Zai Lab Limited Unsponsored ADR stock logo
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Albireo Pharma stock logo

Albireo Pharma NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.43 -0.07 (-0.26%)
Closing price 06/23/2025 03:59 PM Eastern
Extended Trading
$26.42 -0.01 (-0.04%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$49.60 -0.60 (-1.20%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$49.60 -0.01 (-0.01%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$36.01 +1.46 (+4.23%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$36.15 +0.14 (+0.39%)
As of 06/23/2025 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.